CA2504666A1 - Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine - Google Patents

Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine Download PDF

Info

Publication number
CA2504666A1
CA2504666A1 CA002504666A CA2504666A CA2504666A1 CA 2504666 A1 CA2504666 A1 CA 2504666A1 CA 002504666 A CA002504666 A CA 002504666A CA 2504666 A CA2504666 A CA 2504666A CA 2504666 A1 CA2504666 A1 CA 2504666A1
Authority
CA
Canada
Prior art keywords
chloro
mixture
methoxy
ylamino
quinazoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002504666A
Other languages
English (en)
French (fr)
Inventor
Alan Barge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2504666A1 publication Critical patent/CA2504666A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Control And Other Processes For Unpacking Of Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002504666A 2002-11-13 2003-11-07 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine Abandoned CA2504666A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0226434.9 2002-11-13
GBGB0226434.9A GB0226434D0 (en) 2002-11-13 2002-11-13 Combination product
PCT/GB2003/004787 WO2004043472A1 (en) 2002-11-13 2003-11-07 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine

Publications (1)

Publication Number Publication Date
CA2504666A1 true CA2504666A1 (en) 2004-05-27

Family

ID=9947715

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002504666A Abandoned CA2504666A1 (en) 2002-11-13 2003-11-07 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine

Country Status (16)

Country Link
US (1) US20060142297A1 (enExample)
EP (1) EP1562612B1 (enExample)
JP (1) JP2006508953A (enExample)
KR (1) KR20050074573A (enExample)
CN (1) CN100467027C (enExample)
AT (1) ATE456370T1 (enExample)
AU (1) AU2003279456B2 (enExample)
BR (1) BR0316170A (enExample)
CA (1) CA2504666A1 (enExample)
DE (1) DE60331162D1 (enExample)
ES (1) ES2338109T3 (enExample)
GB (1) GB0226434D0 (enExample)
NO (1) NO20052312L (enExample)
NZ (1) NZ539514A (enExample)
WO (1) WO2004043472A1 (enExample)
ZA (1) ZA200503805B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (en) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds as anti cancer agents
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US7462623B2 (en) * 2002-11-04 2008-12-09 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
WO2005044788A1 (ja) 2003-11-11 2005-05-19 Eisai Co., Ltd. ウレア誘導体およびその製造方法
GB0412074D0 (en) 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
KR20090108086A (ko) 2007-01-19 2009-10-14 에자이 알앤드디 매니지먼트 가부시키가이샤 췌장암 치료용 조성물
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
CA2802644C (en) 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US20170022576A1 (en) 2015-03-18 2017-01-26 The Regents Of The University Of California Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
YU22401A (sh) * 1998-09-25 2004-03-12 Warner-Lambert Company Kombinacija acetildinalina sa gemcitabinom, capecitabinom i cisplatinom
AU5636900A (en) * 1999-06-30 2001-01-31 Merck & Co., Inc. Src kinase inhibitor compounds
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
GB0101599D0 (en) * 2001-01-22 2001-03-07 Novartis Ag Organic compounds
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product

Also Published As

Publication number Publication date
ES2338109T3 (es) 2010-05-04
ATE456370T1 (de) 2010-02-15
EP1562612A1 (en) 2005-08-17
NO20052312L (no) 2005-06-06
WO2004043472A1 (en) 2004-05-27
AU2003279456B2 (en) 2007-05-17
DE60331162D1 (de) 2010-03-18
EP1562612B1 (en) 2010-01-27
GB0226434D0 (en) 2002-12-18
CN100467027C (zh) 2009-03-11
BR0316170A (pt) 2005-09-27
AU2003279456A1 (en) 2004-06-03
KR20050074573A (ko) 2005-07-18
CN1711094A (zh) 2005-12-21
NZ539514A (en) 2007-11-30
US20060142297A1 (en) 2006-06-29
ZA200503805B (en) 2006-09-27
JP2006508953A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
EP1562612B1 (en) Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine for use in the treatment or prophlaxix of pancreatic cancer
US20100029673A1 (en) Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use
ES2225545T3 (es) Derivados de quinazolina para el tratamiento de tumores.
US20240360085A1 (en) Glucose Uptake Inhibitors
US20110086870A1 (en) Combination Therapy
JP2024537136A (ja) ＫＲＡＳ Ｇ１２Ｄ阻害剤と汎ＥｒｂＢファミリー阻害剤との併用療法
JP2018052974A (ja) チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
MXPA05001457A (es) Combinacion de inhibidores de tirosina cinasa del receptor del factor de crecimiento endotelial vascular para tratamiento de cancer.
CN102786469B (zh) 邻吡啶酰肼衍生物及其制法和药物组合物与用途
US20070207996A1 (en) Novel Compositions And Methods Of Treatment
TW202320792A (zh) 包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
US20090291961A1 (en) Combination of an mek inhibitor and the src kinase inhibitor azd0530 for use in the treatment of cancer
MXPA06013902A (es) Procedimiento para tratar el crecimiento de celulas anormal.
MXPA05005119A (es) Producto de combinacion de inhibidor de la familia src de cinasas de tirosina de no receptor y gemcitabina.
MXPA06013635A (es) Metodo para el tratamiento de cancer.
CN111718328A (zh) 4-甲基-1h-二芳基吡唑类衍生物在制备抗肿瘤药物中的用途
TWI307628B (en) Use of zd0473 in combination with a non-platinum based anti-cancer agent
HK40109894A (zh) Kras g12d抑制剂与泛erbb家族抑制剂的组合疗法
HK40130580A (zh) 使用mta协作的prmt5抑制剂的癌症治疗
MX2011009413A (es) Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
WO2018106118A1 (en) Treatment of diffuse intrinsic pontine glioma
TW201825092A (zh) 使用包含吲哚嗪并[6, 7-b]吲哚衍生物的醫藥組合物或組合治療小細胞肺癌的方法
JP2014034533A (ja) Ｈｓｐ９０阻害剤とｅｇｆｒチロシンキナーゼ阻害剤の組み合わせ

Legal Events

Date Code Title Description
FZDE Discontinued